
|Articles|November 10, 2021
Emmes Launches Orphan Reach
Advertisement
Emmes, a full service, global clinical research organization(CRO), is launching its new center, Orphan Reach as a ‘rare CRO’.
The new rare disease center will incorporate Emmes’ reputation in public health research across the public sector and biopharmaceutical industry, with the knowledge of Orphan Reach, a UK-based specialty CRO acquired by Emmes in May 2021. The addition of Emmes’ biostatistics, data management, and global clinical trial execution capabilities will enable the center to function as a full, end to end services organization.
The expanded Orphan Reach forms a global specialty center dedicated to the advancement of rare disease research by providing specialized clinical trial design and execution capabilities.
Advertisement
Related to this article

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, outlines how integrating trial matching with standard of care workflows and uniform screening can replace reliance on physician memory with timely, consistent nudges.

Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, makes the case that oncologists must lead discussions about randomization and treatment decisions, while AI can prepare patients beforehand and support them afterward.

In today’s ACT Brief, we examine how AI can cut coordinator screening time, how participants respond to AI-assisted pre-screening, and how FDA approved three new treatments.

Participants in a survey of 354 pre-screening respondents rated AI voice-assisted screening (Clara) favorably and were more likely to schedule and attend study appointments than web-form users, though self-selection means the association cannot be read as causal.

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, explains how AI can unlock unstructured chart data and cut coordinator screening time from hours to minutes, easing a clinical research workforce under strain.

In today’s ACT Brief, we examine what drives inconsistent oncology trial screening, why FDA has reportedly paused its priority voucher pilot, and how patients’ use of AI is reshaping how sponsors communicate with them.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where AI Helps in Patient Conversations About Trials and Where Humans Must Lead
2
Participant Experience with AI-Assisted and Web-Based Clinical Trial Pre-Screening
3
How AI-Enabled Trial Matching Is Changing Who Gets Identified and Screened
4
Measuring Burden Before It Becomes Risk: Coordinator Friction, Tool Fatigue, and Trial Quality
5

